{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:23:24Z","timestamp":1769833404529,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"DOI":"10.7759\/cureus.102637","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:18:40Z","timestamp":1769786320000},"source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Disease-Modifying Antirheumatic Drugs on In-Hospital Outcomes of Patients With COVID-19: A Retrospective Cohort Study and Literature Review"],"prefix":"10.7759","author":[{"given":"Vasiliki","family":"Tasouli-Drakou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"Krutikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Akhondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102903","article-title":"SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis","volume":"59","author":"Mohammadi A","year":"2020","unstructured":"Mohammadi A, Esmaeilzadeh E, Li Y, Bosch RJ, Li JZ. SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis. EBioMedicine. 2020, 59:102903. 10.1016\/j.ebiom.2020.102903","journal-title":"EBioMedicine"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac008","article-title":"SARS-CoV-2 placentitis associated with B.1.617.2 (Delta) variant and fetal distress or demise","volume":"225","author":"Shook LL","year":"2022","unstructured":"Shook LL, Brigida S, Regan J, et al.. SARS-CoV-2 placentitis associated with B.1.617.2 (Delta) variant and fetal distress or demise. J Infect Dis. 2022, 225:754-8. 10.1093\/infdis\/jiac008","journal-title":"J Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead662","article-title":"Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study","volume":"63","author":"Venkat RK","year":"2024","unstructured":"Venkat RK, Wang X, Patel NJ, et al.. Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study. Rheumatology (Oxford). 2024, 63:2828-37. 10.1093\/rheumatology\/kead662","journal-title":"Rheumatology (Oxford)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152025","article-title":"DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study","volume":"55","author":"Di Iorio M","year":"2022","unstructured":"Di Iorio M, Cook CE, Vanni KM, et al.. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study. Semin Arthritis Rheum. 2022, 55:152025. 10.1016\/j.semarthrit.2022.152025","journal-title":"Semin Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani M","year":"2014","unstructured":"Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014, 53:213-22. 10.1093\/rheumatology\/ket260","journal-title":"Rheumatology (Oxford)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13313","article-title":"COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australian\/New Zealand consensus statement","volume":"61","author":"Wang C","year":"2020","unstructured":"Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australian\/New Zealand consensus statement. Australas J Dermatol. 2020, 61:210-6. 10.1111\/ajd.13313","journal-title":"Australas J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12695","article-title":"COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: insights from an analysis of the World Health Organization pharmacovigilance database","volume":"36","author":"Dernoncourt A","year":"2022","unstructured":"Dernoncourt A, Schmidt J, Duhaut P, et al.. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: insights from an analysis of the World Health Organization pharmacovigilance database. Fundam Clin Pharmacol. 2022, 36:199-209. 10.1111\/fcp.12695","journal-title":"Fundam Clin Pharmacol"},{"key":"ref8","unstructured":"Infectious Disease Advisor. Biologic DMARDs linked to worse COVID-19 outcomes in patients with RA. (2025). https.\/\/www.infectiousdiseaseadvisor.com\/news\/biologic-dmards-linked-to-worse-covid-19-outcomes-in-ra-patients\/."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-087467","article-title":"Association between immunosuppressive medications and COVID-19 hospitalisation and death: a retrospective cohort study","volume":"14","author":"Sechrist SJ","year":"2024","unstructured":"Sechrist SJ, Tang E, Arnold BF, Acharya NR. Association between immunosuppressive medications and COVID-19 hospitalisation and death: a retrospective cohort study. BMJ Open. 2024, 14:e087467. 10.1136\/bmjopen-2024-087467","journal-title":"BMJ Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15142","article-title":"Immunosuppression as a risk factor for COVID-19: a meta-analysis","volume":"51","author":"Tassone D","year":"2021","unstructured":"Tassone D, Thompson A, Connell W, et al.. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021, 51:199-205. 10.1111\/imj.15142","journal-title":"Intern Med J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152122","article-title":"Racial differences in persistent glucocorticoid use patterns among medicaid beneficiaries with incident systemic lupus erythematosus","volume":"58","author":"Chandler MT","year":"2023","unstructured":"Chandler MT, Santacroce LM, Costenbader KH, Kim SC, Feldman CH. Racial differences in persistent glucocorticoid use patterns among medicaid beneficiaries with incident systemic lupus erythematosus. Semin Arthritis Rheum. 2023, 58:152122. 10.1016\/j.semarthrit.2022.152122","journal-title":"Semin Arthritis Rheum"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211055817","article-title":"Utilization of glucocorticoids among White and Black patients with systemic lupus erythematosus: observations from the enrollment visit of a prospective registry","volume":"30","author":"Sullivan JK","year":"2021","unstructured":"Sullivan JK, Littlejohn EA. Utilization of glucocorticoids among White and Black patients with systemic lupus erythematosus: observations from the enrollment visit of a prospective registry. Lupus. 2021, 30:2298-303. 10.1177\/09612033211055817","journal-title":"Lupus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00769-2021","article-title":"The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection","volume":"59","author":"Ward D","year":"2022","unstructured":"Ward D, G\u00f8rtz S, Thomson Ernst M, et al.. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. Eur Respir J. 2022, 59:2100769. 10.1183\/13993003.00769-2021","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00342-8","article-title":"TNF-\u03b1 blockers showed prophylactic effects in preventing COVID-19 in patients with rheumatoid arthritis and seronegative spondyloarthropathies: a case-control study","volume":"8","author":"Salesi M","year":"2021","unstructured":"Salesi M, Shojaie B, Farajzadegan Z, Salesi N, Mohammadi E. TNF-\u03b1 blockers showed prophylactic effects in preventing COVID-19 in patients with rheumatoid arthritis and seronegative spondyloarthropathies: a case-control study. Rheumatol Ther. 2021, 8:1355-70. 10.1007\/s40744-021-00342-8","journal-title":"Rheumatol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco M","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, et al.. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020, 79:859-66. 10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic mechanisms of JAK inhibition","volume":"31","author":"Lin CM","year":"2020","unstructured":"Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK inhibition. Mediterr J Rheumatol. 2020, 31:100-4. 10.31138\/mjr.31.1.100","journal-title":"Mediterr J Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05884-4","article-title":"Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials","volume":"40","author":"Patoulias D","year":"2021","unstructured":"Patoulias D, Doumas M, Papadopoulos C, Karagiannis A. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021, 40:4671-4. 10.1007\/s10067-021-05884-4","journal-title":"Clin Rheumatol"},{"key":"ref18","article-title":"Inflammation in COVID-19: from pathogenesis to treatment","volume":"14","author":"Wong RS","year":"2021","unstructured":"Wong RS. Inflammation in COVID-19: from pathogenesis to treatment. Int J Clin Exp Pathol. 2021, 14:831-44.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.072","article-title":"Interleukin-17: a potential therapeutic target in COVID-19","volume":"81","author":"Mendoza VM","year":"2020","unstructured":"Mendoza VM. Interleukin-17: a potential therapeutic target in COVID-19. J Infect. 2020, 81:e136-8. 10.1016\/j.jinf.2020.05.072","journal-title":"J Infect"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1046352","article-title":"Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: a systematic review and meta-analysis","volume":"13","author":"Liu M","year":"2022","unstructured":"Liu M, Wang H, Liu L, et al.. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: a systematic review and meta-analysis. Front Immunol. 2022, 13:1046352. 10.3389\/fimmu.2022.1046352","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1905766","article-title":"Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors","volume":"33","author":"Kridin K","year":"2022","unstructured":"Kridin K, Schonmann Y, Solomon A, et al.. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors. J Dermatolog Treat. 2022, 33:2014-20. 10.1080\/09546634.2021.1905766","journal-title":"J Dermatolog Treat"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795315","article-title":"Immunotherapy of COVID-19: inside and beyond IL-6 signalling","volume":"13","author":"Zizzo G","year":"2022","unstructured":"Zizzo G, Tamburello A, Castelnovo L, et al.. Immunotherapy of COVID-19: inside and beyond IL-6 signalling. Front Immunol. 2022, 13:795315. 10.3389\/fimmu.2022.795315","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with COVID-19","volume":"383","author":"Stone JH","year":"2020","unstructured":"Stone JH, Frigault MJ, Serling-Boyd NJ, et al.. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med. 2020, 383:2333-44. 10.1056\/NEJMoa2028836","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe COVID-19 pneumonia","volume":"384","author":"Rosas IO","year":"2021","unstructured":"Rosas IO, Br\u00e4u N, Waters M, et al.. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N Engl J Med. 2021, 384:1503-16. 10.1056\/NEJMoa2028700","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113928","article-title":"New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers","volume":"175","author":"Chyuan IT","year":"2020","unstructured":"Chyuan IT, Lai JH. New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem Pharmacol. 2020, 175:113928. 10.1016\/j.bcp.2020.113928","journal-title":"Biochem Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2022.03.011","article-title":"COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: a prospective cohort study","volume":"8","author":"Yan D","year":"2022","unstructured":"Yan D, Kolla AM, Young T, et al.. COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: a prospective cohort study. JAAD Int. 2022, 8:31-3. 10.1016\/j.jdin.2022.03.011","journal-title":"JAAD Int"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24096","article-title":"Decreased risk of COVID-19 and long COVID in patients with psoriasis receiving IL-23 inhibitor: a cross-sectional cohort study from China","volume":"10","author":"Hu Y","year":"2024","unstructured":"Hu Y, Huang D, Jiang Y, Yu Q, Lu J, Ding Y, Shi Y. Decreased risk of COVID-19 and long COVID in patients with psoriasis receiving IL-23 inhibitor: a cross-sectional cohort study from China. Heliyon. 2024, 10:e24096. 10.1016\/j.heliyon.2024.e24096","journal-title":"Heliyon"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang DI","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, et al.. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021, 22:2719. 10.3390\/ijms22052719","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076142","article-title":"Prospective roles of tumor necrosis factor-alpha (TNF-\u03b1) in COVID-19: prognosis, therapeutic and management","volume":"24","author":"Mohd Zawawi Z","year":"2023","unstructured":"Mohd Zawawi Z, Kalyanasundram J, Mohd Zain R, Thayan R, Basri DF, Yap WB. Prospective roles of tumor necrosis factor-alpha (TNF-\u03b1) in COVID-19: prognosis, therapeutic and management. Int J Mol Sci. 2023, 24:6142. 10.3390\/ijms24076142","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48145-x","article-title":"COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients","volume":"13","author":"Kasten MJ","year":"2023","unstructured":"Kasten MJ, Lahr BD, Parisapogu A, et al.. COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients. Sci Rep. 2023, 13:21249. 10.1038\/s41598-023-48145-x","journal-title":"Sci Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0b013e318296f299","article-title":"Teriflunomide","volume":"3","author":"Oh J","year":"2013","unstructured":"Oh J, O'Connor PW. Teriflunomide. Neurol Clin Pract. 2013, 3:254-60. 10.1212\/CPJ.0b013e318296f299","journal-title":"Neurol Clin Pract"},{"key":"ref32","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"30","author":"Osiri M","year":"2003","unstructured":"Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2003, 30:1182-90.","journal-title":"J Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier E","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020, 16:155-66. 10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103049","article-title":"COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: first national case series","volume":"53","author":"Luetic G","year":"2021","unstructured":"Luetic G, Menichini ML, Burgos M, et al.. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: first national case series. Mult Scler Relat Disord. 2021, 53:103049. 10.1016\/j.msard.2021.103049","journal-title":"Mult Scler Relat Disord"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002094","article-title":"Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease","volume":"33","author":"Scharrer S","year":"2021","unstructured":"Scharrer S, Kutschera M, Weseslindtner L, Primas C, Vogelsang H. Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2021, 33:443-7. 10.1097\/MEG.0000000000002094","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/art.41469","article-title":"Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis","volume":"73","author":"Putman M","year":"2021","unstructured":"Putman M, Chock YP, Tam H, et al.. Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheumatol. 2021, 73:36-47. 10.1002\/art.41469","journal-title":"Arthritis Rheumatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217690","article-title":"Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19","volume":"79","author":"Konig MF","year":"2020","unstructured":"Konig MF, Kim AH, Scheetz MH, et al.. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020, 79:1386-8. 10.1136\/annrheumdis-2020-217690","journal-title":"Ann Rheum Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101858","article-title":"The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: a systematic review of clinical evidence","volume":"79","author":"Al-Haideri MT","year":"2023","unstructured":"Al-Haideri MT, Mannani R, Kaboli R, et al.. The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: a systematic review of clinical evidence. Transpl Immunol. 2023, 79:101858. 10.1016\/j.trim.2023.101858","journal-title":"Transpl Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108324","article-title":"Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic","volume":"101","author":"Ganjei Z","year":"2021","unstructured":"Ganjei Z, Faraji Dana H, Ebrahimi-Dehkordi S, Alidoust F, Bahmani K. Methotrexate as a safe immunosuppressive agent during the COVID-19 pandemic. Int Immunopharmacol. 2021, 101:108324. 10.1016\/j.intimp.2021.108324","journal-title":"Int Immunopharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100789","article-title":"COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis","volume":"33","author":"Gerayeli FV","year":"2021","unstructured":"Gerayeli FV, Milne S, Cheung C, et al.. COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021, 33:100789. 10.1016\/j.eclinm.2021.100789","journal-title":"EClinicalMedicine"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01209-2021","article-title":"Asthma and COVID-19 risk: a systematic review and meta-analysis","volume":"59","author":"Sunjaya AP","year":"2022","unstructured":"Sunjaya AP, Allida SM, Di Tanna GL, Jenkins CR. Asthma and COVID-19 risk: a systematic review and meta-analysis. Eur Respir J. 2022, 59:2101209. 10.1183\/13993003.01209-2021","journal-title":"Eur Respir J"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/idr17040074","article-title":"Impact of COVID-19 vaccination on hospitalization and mortality: a comparative analysis of clinical outcomes during the early phase of the pandemic","volume":"17","author":"Gardu\u00f1o-Orbe B","year":"2025","unstructured":"Gardu\u00f1o-Orbe B, Palma-Ram\u00edrez PS, L\u00f3pez-Ortiz E, et al.. Impact of COVID-19 vaccination on hospitalization and mortality: a comparative analysis of clinical outcomes during the early phase of the pandemic. Infect Dis Rep. 2025, 17:74. 10.3390\/idr17040074","journal-title":"Infect Dis Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/457278-the-impact-of-disease-modifying-antirheumatic-drugs-on-in-hospital-outcomes-of-patients-with-covid-19-a-retrospective-cohort-study-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:18:42Z","timestamp":1769786322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/457278-the-impact-of-disease-modifying-antirheumatic-drugs-on-in-hospital-outcomes-of-patients-with-covid-19-a-retrospective-cohort-study-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.102637","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}